共查询到20条相似文献,搜索用时 10 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
9.
Rebecca Chester M.D. Sheila Sahni M.D. Tracy Huynh M.D. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(7):1203-1205
We describe the case of a 62‐year‐old female presenting with new onset progressive dyspnea on exertion and a new diagnosis of aortic stenosis. Transesophageal echocardiography showed fusion of the aortic valve leaflets suspicious for bicuspid aortic valve with dilated ascending aorta. Surgical replacement of the valve revealed a unicuspid aortic valve with one true commissure at the level of the left and noncoronary cusps. The case is supported by clinical, echocardiographic and angiographic imaging and discussion of current imaging modalities used in diagnosis of aortic valve pathology. 相似文献
10.
11.
Transcatheter Aortic Valve Replacement in Bicuspid Aortic Stenosis Using Lotus Valve System 下载免费PDF全文
Albert W. Chan MD MSC FRCPC FACC FSCAI Daniel Wong MD MPH FRCSC Jahangir Charania MD FRCPC 《Catheterization and cardiovascular interventions》2017,90(1):157-163
Bicuspid aortic stenosis (BAS) has been excluded in clinical trials on transcatheter aortic valve replacement (TAVR) due to the presumed uneven expansion of the aortic prosthesis, leading to significant paravalvular regurgitation (PVR). There is no transcatheter heart valve (THV) commercially approved for treating BAS. The Lotus Valve System mitigates PVR by possessing an adaptive seal and being fully re‐positionable. The latter is also important in preventing embolization, as the location of prosthesis fixation in BAS could be variable due to the presence of less expandable raphe. We report our early experience with the Lotus Valve System in three consecutive TAVR for BAS. They all provide good clinical and hemodynamic results without significant PVR. We conclude that the use of Lotus Valve System for treating BAS is feasible and safe, and may have advantages over the previous generation TAVR systems. © 2016 Wiley Periodicals, Inc. 相似文献
12.
David A. Roy Ulrich Schaefer Victor Guetta David Hildick-Smith Helge Möllmann Nicholas Dumonteil Thomas Modine Johan Bosmans Anna Sonia Petronio Neil Moat Axel Linke Cesar Moris Didier Champagnac Radoslaw Parma Andrzej Ochala Diego Medvedofsky Tiffany Patterson Felix Woitek Marjan Jahangiri Jean-Claude Laborde Stephen J. Brecker 《Journal of the American College of Cardiology》2013
13.
Joachim Schofer Antonio Colombo Silvio Klugmann Jean Fajadet Federico DeMarco Didier Tchétché Francesco Maisano Giuseppe Bruschi Azeem Latib Klaudija Bijuklic Neil Weissman Reginald Low Martyn Thomas Christopher Young Simon Redwood Michael Mullen John Yap Eberhard Grube Georg Nickenig Jan-Malte Sinning Karl Eugen Hauptmann Ivar Friedrich Michael Lauterbach Michael Schmoeckel Charles Davidson Thierry Lefevre 《Journal of the American College of Cardiology》2014
14.
15.
16.
Ian T. Meredith AM Darren L. Walters Nicolas Dumonteil Stephen G. Worthley Didier Tchétché Ganesh Manoharan Daniel J. Blackman Gilles Rioufol David Hildick-Smith Robert J. Whitbourn Thierry Lefèvre Rüdiger Lange Ralf Müller Simon Redwood Dominic J. Allocco Keith D. Dawkins 《Journal of the American College of Cardiology》2014
Background
Transcatheter aortic valve replacement provides results comparable to those of surgery in patients at high surgical risk, but complications can impact long-term outcomes. The Lotus valve, designed to improve upon earlier devices, is fully repositionable and retrievable, with a unique seal to minimize paravalvular regurgitation (PVR).Objectives
The prospective, single-arm, multicenter REPRISE II study (REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System: Evaluation of Safety and Performance) evaluated the transcatheter valve system for treatment of severe symptomatic calcific aortic valve stenosis.Methods
Patients (n = 120; aortic annulus 19 to 27 mm) considered by a multidisciplinary heart team to be at high surgical risk received the valve transfemorally. The primary device performance endpoint, 30-day mean pressure gradient, was assessed by an independent echocardiographic core laboratory and compared with a pre-specified performance goal. The primary safety endpoint was 30-day mortality. Secondary endpoints included safety/effectiveness metrics per Valve Academic Research Consortium criteria.Results
Mean age was 84.4 years, 57% of the patients were female, and 76% were New York Heart Association functional class III/IV. Mean aortic valve area was 0.7 ± 0.2 cm2. The valve was successfully implanted in all patients, with no cases of valve embolization, ectopic valve deployment, or additional valve implantation. All repositioning (n = 26) and retrieval (n = 6) attempts were successful; 34 patients (28.6%) received a permanent pacemaker. The primary device performance endpoint was met, because the mean gradient improved from 46.4 ± 15.0 mm Hg to 11.5 ± 5.2 mm Hg. At 30 days, the mortality rate was 4.2%, and the rate of disabling stroke was 1.7%; 1 (1.0%) patient had moderate PVR, whereas none had severe PVR.Conclusions
REPRISE II demonstrates the safety and effectiveness of the Lotus valve in patients with severe aortic stenosis who are at high surgical risk. The valve could be positioned successfully with minimal PVR. (REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Evaluation of Safety and Performance; NCT01627691) 相似文献17.
18.
19.